Citations

Clear

4847 citation(s) found for "Tu, Eric".

Tubularization of the gastric pouch helps sustain weight loss after transoral outlet reduction for post-Roux-en-Y gastric bypass weight recurrence
Abboud, Donna Maria , Ghazi, Rabih , Brunaldi, Vitor , Gala, Khushboo , Baroud, Serge , Kerbage, Anthony , Abdul-Razzak, Farah, Annan, Karim Al , Rapaka, Babusai , Yao, Rebecca , AbdulRazzak, Farah, Al Annan, Karim, Vargas, Eric J , Storm, Andrew C , Abboud, Donna M , Vargas, Eric J. , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Endoscopy International Open | June 26, 2023 | Volume: 11 | Issue: 09 | Pages: E829-E834

10.1055/a-2117-8113 | PMID 37719801 Get It

Abstract Background and study aims Traditional transoral outlet reduction (TORe) is a minimally invasive endoscopic approach focused on reducing the aperture of the gastrojejunal (GJ) anastomosis, while the tubular transoral outlet reduction (tTORe) consists of tabularization of the distal pouch utilizing an O-shape gastroplasty suturing pattern. The primary aim of this study was to compare short-term weight loss between TORe and tTORe. Patients and methods Retrospective analysis of a prospectively maintained database was conducted at a tertiary care bariatric center of excellence. The study included patients with history of Roux-en-Y gastric bypass (RYGB) who had an endoscopic revision by TORe or tTORe and had follow-up data in their electronic medical record. The primary outcome was percent total body weight loss (%TBWL). Results A total of 128 patients were included (tTORe=85, TORe=43). At 3 and 6 months, the tTORe and TORe cohorts presented similar %TBWL (3 months: 8.5±4.9 vs. 7.3±6.0, P = 0.27 and 6 months: 8.1±7.4 vs. 6.8±5.6, P = 0.44). At 9 months, there was a trend toward greater weight loss in the tTORe cohort (9.7±8.6% vs. 5.1±6.8%, P = 0.053). At 12 months, the %TBWL was significantly higher in the tubularization group compared to the standard group (8.2±10.8 vs. 2.3±7.3%, P = 0.01). Procedure time was significantly different between both groups (60.5 vs. 53.4 minutes, P = 0.03). The adverse events rate was similar between groups (8.2% vs. 7.0% for tTORe and TORe, respectively, P = 0.61). Conclusions The tTORe enhances efficacy and durability of the standard procedure without adding significant procedure-related risks.
Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure
Alkhatry, Maryam, Rapaka, Babusai , Maselli, Daniel B. , Abboud, Donna Maria , Brunaldi, Vitor , Mahmoud, Tala , Ghazi, Rabih , Razzak, Farah Abdul, Gala, Khushboo, Joudah, Imad, Housen, Fedaa, Qadi, Sana Al, Brunaldi, Vitor Ottoboni , Abdul Razzak, Farah, Vargas, Eric J , Storm, Andrew C , Abboud, Donna M , Gala, Khushboo , Vargas, Eric J. , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Endoscopy | June 26, 2023 | Volume: 55 | Issue: 11 | Pages: 1028-1034

10.1055/a-2117-6274 | PMID 37364600 Get It

Background The primary obesity surgery endoluminal 2.0 (POSE 2.0) procedure involves full-thickness gastric body plications to narrow the stomach using durable suture anchor pairs. We evaluated POSE 2.0 as a treatment strategy for nonalcoholic fatty liver disease (NAFLD) in patients with obesity. Methods Adults with obesity and NAFLD were prospectively allocated based on their preference to undergo POSE 2.0 with lifestyle modification or lifestyle modification alone (control). Primary end points were improvement in controlled attenuation parameter (CAP) and resolution of hepatic steatosis at 12 months. Secondary end points included %total body weight loss (%TBWL), change in serum measures of hepatic steatosis and insulin resistance, and procedure safety. Results 42 adult patients were included (20 in the POSE 2.0 arm and 22 in the control arm). At 12 months, POSE 2.0 significantly improved CAP, whereas lifestyle modification alone did not (P < 0.001 for POSE 2.0; P = 0.24 for control). Similarly, both resolution of steatosis and %TBWL were significantly higher with POSE 2.0 than with control at 12 months. Compared with controls, POSE 2.0 significantly improved liver enzymes, hepatic steatosis index, and aspartate aminotransferase to platelet ratio at 12 months. There were no serious adverse events. Conclusion POSE 2.0 was effective for NAFLD in patients with obesity, with good durability and safety profile.
Hepatic Angiosarcomas With Sinusoidal Growth Patterns
Chen, Zongming Eric, Wu, Tsung‐Teh, Yasir, Saba , Soon, Gwyneth Shook Ting , Torbenson, Michael

Mayo Clinic

American Journal of Surgical Pathology | June 26, 2023 | Volume: 47 | Issue: 9 | Pages: 1045-1051

10.1097/pas.0000000000002082 | PMID 37357916 Get It

Hepatic angiosarcomas are aggressive malignant tumors of the liver with variable morphology. One of the rare morphologies is that of the sinusoidal growth pattern, which is challenging to diagnose because of its subtle imaging and morphologic findings. This retrospective study characterizes the clinical, histologic, and immunohistochemical features of sinusoidal hepatic angiosarcomas. Thirteen cases were included in the study, comprising 12 (92.3%) needle core biopsies and 1 wedge biopsy; one of the needle biopsies also had a subsequent resection specimen available for review. Multiple biopsies were needed to make the diagnosis in 4 cases. At least moderate sinusoidal dilatation was seen in 53.8% of cases. Increased cellularity within the sinusoids was seen at both low-power and high-power magnification (69.2% and 84.6%, respectively). Cytologic atypia ranged from mild to marked. Multinucleated tumor cells were present in most cases (10/13 cases) but were often sparse. Mitotic activity was identified in 5/13 cases. ERG immunostains were more reliable than CD31 and CD34 in identifying the tumor cells. Ki-67 proliferative index ranged from 5% to 30%. p53 immunostains were available in 9 cases and c-MYC in 7 cases; they were positive in 62.5% and 33.3% of cases, respectively and had a mutually exclusive staining pattern. In summary, this rare pattern of hepatic angiosarcoma is challenging to diagnose but has distinctive morphologic findings that can be supplemented with immunostains to establish the diagnosis.
Longitudinal estimated glomerular filtration rate (eGFR) modeling in long‐term renal function to inform clinical trial design in kidney transplantation
Kosinski, Luke , Frey, Eric C. , Klein, Amanda , O’Doherty, Inish , Romero, Klaus , Stegall, Mark D. , Helanterä, Ilkka , Gaber, A. Osama , Fitzsimmons, William E. , Aggarwal, Varun , Stegall, Mark D , Gaber, Ahmed Osama

Mayo Clinic

Clinical and Translational Science | June 24, 2023 | Volume: 16 | Issue: 9 | Pages: 1680-1690

10.1111/cts.13579 | PMID 37350196 Get It

AbstractKidney transplantation is the preferred treatment for individuals with end‐stage kidney disease. From a modeling perspective, our understanding of kidney function trajectories after transplantation remains limited. Current modeling of kidney function post‐transplantation is focused on linear slopes or percent decline and often excludes the highly variable early timepoints post‐transplantation, where kidney function recovers and then stabilizes. Using estimated glomerular filtration rate (eGFR), a well‐known biomarker of kidney function, from an aggregated dataset of 4904 kidney transplant patients including both observational studies and clinical trials, we developed a longitudinal model of kidney function trajectories from time of transplant to 6 years post‐transplant. Our model is a nonlinear, mixed‐effects model built in NONMEM that captured both the recovery phase after kidney transplantation, where the graft recovers function, and the long‐term phase of stabilization and slow decline. Model fit was assessed using diagnostic plots and individual fits. Model performance, assessed via visual predictive checks, suggests accurate model predictions of eGFR at the median and lower 95% quantiles of eGFR, ranges which are of critical clinical importance for assessing loss of kidney function. Various clinically relevant covariates were also explored and found to improve the model. For example, transplant recipients of deceased donors recover function more slowly after transplantation and calcineurin inhibitor use promotes faster long‐term decay. Our work provides a generalizable, nonlinear model of kidney allograft function that will be useful for estimating eGFR up to 6 years post‐transplant in various clinically relevant populations.
Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
King, Sontoria D. , Veliginti, Swathi , Brouwers, Martijn C.G.J. , Ren, Zhewen , Zheng, Wei , Setiawan, Veronica Wendy , Wilkens, Lynne R. , Shu, Xiao‐Ou , Arslan, Alan A. , Freeman, Laura E. Beane , Bracci, Paige M. , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Haiman, Christopher A. , Visvanathan, Kala , White, Emily , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Brennan, Paul , Buring, Julie E. , Fuchs, Charles S. , Gaziano, J. Michael , Giovannucci, Edward L. , Hackert, Thilo , Hassan, Manal M. , Kurtz, Robert C. , Lee, I‐Min , Oberg, Ann L. , Porta, Miquel , Rothman, Nathaniel , Sesso, Howard D. , Wentzensen, Nicolas , Yu, Kai , Wolpin, Brian M. , Li, Donghui , Patel, Alpa V. , Peters, Ulrike , Ríboli, Elio , Zhong, Jun, Antwi, Samuel O. , Zhong, Jun , Setiawan, Veronica W , Beane Freeman, Laura E , Canzian, Federico , Du, Mengmeng , Gallinger, Steven , Giles, Graham G , Goodman, Phyllis J , Haiman, Christopher A , Kogevinas, Manolis , Kooperberg, Charles , Marchand, Loïc Le , Neale, Rachel E , Visvanathan, Kala , White, Emily , Albanes, Demetrius , Andreotti, Gabriella , Babic, Ana , Berndt, Sonja I , Brais, Lauren K , Brennan, Paul , Buring, Julie E , Chaffee, Kari G. , Bamlet, William R , Chanock, Stephen Jacob , Fuchs, Charles S , Gaziano, J Michael , Giovannucci, Edward L , Hackert, Thilo , Hassan, Manal M , Katzke, Verena , Kurtz, Robert C , Lee, I-Min , Malats, Nuria , Murphy, Neil , Oberg, Ann L , Orlow, Irene , Porta, Miquel , Real, Francisco X , Rothman, Nathaniel , Sesso, Howard D , Silverman, Debra T. , Thompson, Ian M , Wactawski-Wende, Jean , Wang, Xiaoliang , Wentzensen, Nicolas , Yu, Herbert , Zeleniuch-Jacquotte, Anne , Yu, Kai , Wolpin, Brian M , Duell, Eric J , Li, Donghui , Hung, Rayjean J , Perdomo, Sandra , McCullough, Marjorie L , Freedman, Neal D , Patel, Alpa V , Peters, Ulrike , Riboli, Elio , Sund, Malin , Tjønneland, Anne , Zhong, Jun , Van Den Eeden, Stephen K , Kraft, Peter , Risch, Harvey A , Amundadottir, Laufey , Klein, Alison P , Stolzenberg-Solomon, Rachael , Antwi, Samuel O , Arslan, Alan A , Shu, Xiao-Ou , Zheng, Wei , Wilkens, Lynne R , Canzian, Federico , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Albanes, Demetrius , Rabe, Kari G. , Bamlet, William R. , Malats, Núria , Murphy, Neil , Orlow, Irene , Real, Francisco X. , Thompson, Ian M. , Wactawski‐Wende, Jean , Wang, Xiaoliang , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Duell, Eric J. , Hung, Rayjean J. , McCullough, Marjorie L. , Freedman, Neal D. , Sund, Malin , Tjønneland, Anne , Kraft, Peter , Risch, Harvey A. , Ámundadóttir, Laufey T. , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 24, 2023 | Volume: 32 | Issue: 9 | Pages: 1265-1269

10.1158/1055-9965.epi-23-0453 | PMID 37351909 Get It

Abstract Background: There are conflicting data on whether nonalcoholic fatty liver disease (NAFLD) is associated with susceptibility to pancreatic cancer. Using Mendelian randomization (MR), we investigated the relationship between genetic predisposition to NAFLD and risk for pancreatic cancer. Methods: Data from genome-wide association studies (GWAS) within the Pancreatic Cancer Cohort Consortium (PanScan; cases n = 5,090, controls n = 8,733) and the Pancreatic Cancer Case Control Consortium (PanC4; cases n = 4,163, controls n = 3,792) were analyzed. We used data on 68 genetic variants with four different MR methods [inverse variance weighting (IVW), MR-Egger, simple median, and penalized weighted median] separately to predict genetic heritability of NAFLD. We then assessed the relationship between each of the four MR methods and pancreatic cancer risk, using logistic regression to calculate ORs and 95% confidence intervals (CI), adjusting for PC risk factors, including obesity and diabetes. Results: No association was found between genetically predicted NAFLD and pancreatic cancer risk in the PanScan or PanC4 samples [e.g., PanScan, IVW OR, 1.04; 95% confidence interval (CI), 0.88–1.22; MR-Egger OR, 0.89; 95% CI, 0.65–1.21; PanC4, IVW OR, 1.07; 95% CI, 0.90–1.27; MR-Egger OR, 0.93; 95% CI, 0.67–1.28]. None of the four MR methods indicated an association between genetically predicted NAFLD and pancreatic cancer risk in either sample. Conclusions: Genetic predisposition to NAFLD is not associated with pancreatic cancer risk. Impact: Given the close relationship between NAFLD and metabolic conditions, it is plausible that any association between NAFLD and pancreatic cancer might reflect host metabolic perturbations (e.g., obesity, diabetes, or metabolic syndrome) and does not necessarily reflect a causal relationship between NAFLD and pancreatic cancer.
Genetic control of mRNA splicing as a potential mechanism for incomplete penetrance of rare coding variants
Einson, Jonah , Glinos, Dafni A. , Boerwinkle, Eric , Fornage, Myriam , Gabriel, Stacey , Germer, Søren , Gibbs, Richard A. , Kaplan, Robert C. , Nassir, Rami , Meyers, Deborah A. , Rienstra, Michiel , Saferali, Aabida , Shoemaker, M. Benjamin , Silverman, Edwin K. , Smith, Albert V. , Castel, Stephane E. , Iossifov, Ivan , Lappalainen, Tuuli , Rienstra, Michiel , Smith, Albert V , Nassir, Rami , Castaldi, Peter J. , Darbar, Dawood , Andrade, Mariza de , Ellinor, Patrick T. , Hersh, Craig P. , Johnsen, Jill M , Konkle, Barbara A. , Kooperberg, Charles , Loos, Ruth J. F. , Mitchell, Braxton D. , Psaty, Bruce M. , Vasan, Ramachandran S. , Rich, Stephen S. , Rotter, Jerome I. , Mohammadi, Pejman

Mayo Clinic

GENETICS | June 24, 2023 | Volume: 224 | Issue: 4 | Pages: No page available

10.1093/genetics/iyad115 | PMID 37348055 Get It

Abstract Exonic variants present some of the strongest links between genotype and phenotype. However, these variants can have significant inter-individual pathogenicity differences, known as variable penetrance. In this study, we propose a model where genetically controlled mRNA splicing modulates the pathogenicity of exonic variants. By first cataloging exonic inclusion from RNA-sequencing data in GTEx V8, we find that pathogenic alleles are depleted on highly included exons. Using a large-scale phased whole genome sequencing data from the TOPMed consortium, we observe that this effect may be driven by common splice-regulatory genetic variants, and that natural selection acts on haplotype configurations that reduce the transcript inclusion of putatively pathogenic variants, especially when limiting to haploinsufficient genes. Finally, we test if this effect may be relevant for autism risk using families from the Simons Simplex Collection, but find that splicing of pathogenic alleles has a penetrance reducing effect here as well. Overall, our results indicate that common splice-regulatory variants may play a role in reducing the damaging effects of rare exonic variants.
The association of amyloid‐beta, tau, and cerebrovascular biomarkers with neurodegeneration in dementia with Lewy bodies
Przybelski, Scott A. , Lesnick, Timothy G. , Graff‐Radford, Jonathan , Fields, Julie A. , Savica, Rodolfo , Graff‐Radford, Neill R. , Lowe, Val J. , Petersen, Ronald C. , Ferreira, Daniel , Schwarz, Christopher G. , Diaz‐Galvan, Patricia , Senjem, Matthew L. , Ferman, Tanis J. , Jack, Clifford R. , Westman, Eric , Boeve, Bradley F. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | June 16, 2023 | Volume: 19 | Issue: S3 | Pages: No page available

10.1002/alz.067971 Get It

AbstractBackgroundDementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia, after Alzheimer’s disease (AD). While alpha‐synuclein pathology is the hallmark of DLB, AD and cerebrovascular pathologies are common in DLB patients. However, the contribution of these pathologies towards neurodegeneration in DLB is largely unknown. We investigated associations of amyloid‐beta, tau, and cerebrovascular biomarkers with regional gray matter (GM) volume in DLB patients and cognitively unimpaired (CU) controls.MethodWe included 30 DLB patients (69.3±10.2 years old, 87% men) and 100 CU individuals balanced on age and sex (Table 1). We used 11C‐Pittsburgh Compound‐B (PiB) and 18F‐Flortaucipir positron emission tomography (PET) to assess amyloid‐beta and tau in‐vivo. We used structural MRI to assess white matter hyperintensity (WMH) volume, a marker of cerebrovascular lesion load, and regional GM volume (a marker of neurodegeneration). We used correlations and ANCOVA in the whole dataset and structural equation modelling in the DLB patients to investigate associations of WMH volume and regional amyloid‐beta and tau PET standardized uptake value ratios (SUVRs) with regional GM volume.ResultDLB patients showed lower GM volume across all cortical and subcortical regions except for cuneus, putamen, and pallidum (Fig.1). Greater WMH volume was associated with lower volume in the medial and orbital frontal cortices, insula, fusiform cortex, and thalamus in DLB patients (Fig.2). Greater PiB SUVR was associated with lower volume in the inferior temporal cortex, while Flortaucipir SUVR did not correlate with GM volume (Fig.2). Structural equation modelling showed that higher age and positivity for the APOE e4 genotype were significant predictors of greater WMH, and WMH in turn was a significant predictor of GM volume in medial and orbital frontal cortices, insula, and inferior temporal cortex (Fig.3). In contrast, we observed two distinct paths for the fusiform cortex, with age having an effect through PiB and Flortaucipir SUVRs on the one path, and through WMH on the other path (Fig.3).ConclusionDLB patients have widespread cortical atrophy, most of which likely is influenced by alpha‐synuclein pathology. Although amyloid‐beta, tau, and cerebrovascular pathologies often coexist in DLB, their contributions to neurodegeneration seem to be region specific.
Neuropathological features of antemortem atrophy‐based subtypes of Alzheimer’s disease
Frerich, Simon , Muehlboeck, J‐Sebastian, Mohanty, Rosaleena , Ferreira, Daniel , Grothe, Michel J. , Westman, Eric

Mayo Clinic

Alzheimer's & Dementia | June 16, 2023 | Volume: 19 | Issue: S3 | Pages: No page available

10.1002/alz.067339 Get It

AbstractBackgroundPure Alzheimer’s disease (AD), characterized by combined amyloid and tau pathology, is not the most prevalent form of the disease as non‐AD pathologies (e.g., alpha‐synuclein and TDP‐43) are commonly observed postmortem. The role of AD and non‐AD pathologies is unclear in relation to disease heterogeneity. Therefore, we investigated whether antemortem MRI‐based atrophy subtypes of AD differ in postmortem neuropathological features and comorbid non‐AD pathologies.MethodsWe selected individuals from the ADNI with antemortem MRI evaluating brain atrophy within 2 years before death; antemortem diagnosis of AD dementia/mild cognitive impairment; and a postmortem‐confirmed AD neuropathologic change. Antemortem atrophy subtypes were modeled as continuous phenomena using a recent conceptual framework: typicality (spanning limbic predominant AD to hippocampal sparing AD) and severity (spanning typical AD to minimal atrophy AD). Postmortem neuropathological evaluation included AD hallmarks (amyloid‐beta, tau), non‐AD pathologies (alpha‐synuclein, TDP‐43) and concomitant pathological burden. Partial correlations assessed the associations between antemortem atrophy subtype dimensions and postmortem neuropathological outcomes.ResultsIn 31 individuals (mean age = 80y, 26% females), antemortem typicality was significantly associated with neuropathological features: amyloid‐beta (rho = ‐0.39 overall), tau (rho = ‐0.38 regionally), neuritic plaque density (rho = ‐0.4 overall), alpha‐synuclein (rho = ‐0.39 regionally), TDP‐43 (rho = ‐0.49 overall), and concomitance pathological burden (rho = ‐0.59 regionally). This suggests that limbic predominant AD was associated with higher burden of these pathologies compared to hippocampal sparing AD. Antemortem severity was significantly associated with concomitant pathological burden (rho = ‐0.43 regionally), such that typical AD showed higher burden than minimal atrophy AD.ConclusionsBased on our direct antemortem‐to‐postmortem validation, we hypothesize that: (a) typicality and severity in atrophy reflect differential aspects of susceptibility of the brain to AD and non‐AD pathologies; (b) limbic predominant AD and typical AD subtypes may share similar biological pathways, making them more vulnerable to the investigated AD and non‐AD pathologies compared to hippocampal sparing AD, which may follow a different biological pathway. Our findings provide a deeper understanding of associations of atrophy subtypes in AD with different pathologies, enhancing prevailing knowledge of biological heterogeneity in AD.
Degeneration of the cholinergic system in subjective cognitive decline: A systematic review
Alemany, Iris, Rodriguez‐Hernandez, Marta A., Němý, Milan , Cedrés, Nira , Alemany, Iris, Diaz‐Galvan, Patricia , Westman, Eric , Barroso, José , Ferreira, Daniel

Mayo Clinic

Alzheimer's & Dementia | June 16, 2023 | Volume: 19 | Issue: S3 | Pages: No page available

10.1002/alz.064480 Get It

AbstractBackgroundSubjective cognitive decline (SCD) is topic of mayor interest when identifying individuals at risk for future cognitive impairment and dementia. The degeneration of the cholinergic system is linked to the onset of cognitive symptoms in mild cognitive impairment (MCI) and dementia. Yet, it is uncertain whether the neurodegeneration of the cholinergic system is already present in SCD individuals. This review is the first to synthetize the available data on the association of SCD with multiple markers of degeneration in the cholinergic system.MethodFollowing the PRISMA guidelines, original articles focused on the association of SCD and the cholinergic system were extracted from three databases: Pubmed, WOS and Scopus, in November 2021. Two researchers reviewed the studies independently in a 2‐stepwise approach. The quality of the studies and risk of bias were assessed using FLC 3.0, that allows to systematically evaluate the studies and summarize them easily.ResultAmong 119 studies found in our systematic search, 11 were included in the current review. Seven were cross‐sectional and 4 had a longitudinal design. Most of the studies operationalized SCD based on amnestic cognitive complaints (n = 9, 82%). The cholinergic system measures were based on neuroimaging markers for volume of the basal forebrain and/or functional connectivity, transcranial magnetic stimulation, or biofluid markers (i.e. cerebrospinal fluid (CSF) and plasma). The studies focused on association of SCD with basal brain atrophy, 75% reported reduce volumes in SCD; From those focused on functional connectivity of the cholinergic system, 33% reported poorer connectivity in SCD.ConclusionBased on scientific evidence, neurodegeneration of the cholinergic system is already evident during SCD. Using multiple cholinergic biomarkers, degeneration of cholinergic system in SCD seems to occur with significant structural and functional degeneration of cholinergic nuclei in the basal forebrain and their connections with other brain areas. These findings have implications on identifying individuals with increased vulnerability to cognitive impairment and for targeting individuals that might benefit from cholinergic‐target treatments. Further research is needed to elucidate potential contributors to the cholinergic degeneration in SCD and its impact on cognition and clinical progression.
Associations between cerebrospinal fluid biomarkers and brain regions of relevance for very early Alzheimer’s disease processes
Sacuiu, Simona , Blennow, Kaj , Lindberg, Olof , Zettergren, Anna , Seidu, Nazib M. , Kern, Silke , Sterner, Therese Rydberg , Zetterberg, Henrik , Ferreira, Daniel , Westman, Eric , Skoog, Ingmar

Mayo Clinic

Alzheimer's & Dementia | June 16, 2023 | Volume: 19 | Issue: S2 | Pages: No page available

10.1002/alz.061821 Get It

AbstractBackgroundThe relation between cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD) and neurodegeneration and brain regions of relevance for very early pathological processes in AD is poorly understood. This study aims to investigate cross‐sectional associations between the CSF biomarkers amyloid‐β1‐42 (Aβ42), total‐tau (T‐tau), phosphorylated‐tau (P‐tau), neurogranin (Ng) and neurofilament light (NfL) protein and normalized intracranial volumes of the hippocampus, amygdala, entorhinal cortex and basal forebrain observed on structural magnetic resonance imaging (MRI) in cognitively healthy 70‐year olds from the general population.MethodThe analyses included 226 cognitively normal individuals (clinical dementia rating of zero), examined during 2014‐2016 as part of the population‐based Gothenburg H70 Birth Cohort Studies in Sweden. The study participants had undergone lumbar puncture examination to extract CSF samples for biomarker measurements (pg/mL), MRI scan (volumes in mm³), and apolipoprotein E (APOE) genotyping. Linear regressions, adjusted for sex, were used to examine potential associations.ResultElevated CSF T‐tau, P‐tau, and Ng concentrations were associated with smaller volumes of the hippocampus, amygdala, and entorhinal cortex among individuals with amyloid pathology (p = 8×10−8 – 0.04) and among APOE ε4 carriers (p = 8×10−5 – 0.04). In addition, elevated CSF T‐tau, P‐tau, and Ng concentrations were associated with larger basal forebrain among individuals without pathological Aβ42 (p = 0.001 – 0.01) and among APOE ε4 non‐carriers (p = 0.004 – 0.02).ConclusionThe results of our study suggest that among cognitively normal adults who have amyloid pathology or genetic susceptibility to AD, there are associations between axonal degeneration, tangle pathology, and synapse loss and decreased volumes of AD vulnerable brain regions. The associations between elevated CSF biomarkers and larger basal forebrain in cognitively normal individuals were unexpected, but could possibly be explained by compensatory mechanisms or an inflammatory response (generating neuronal or glial swelling) as a very early reaction to the presence of increased levels of tau and Ng. Our findings highlight the clinical pathophysiological relevance of CSF biomarkers of AD and neurodegeneration and how they relate to AD specific brain regions seen on structural MRI in 70‐year‐olds that may be at risk to develop dementia.